ADERIS PHARMACEUTICALS, INC. 85 Main Street Hopkinton, MA 01757 Phone: (508) 497-2300 Fax: (508) 497-9964 www.aderis.com Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes novel small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases. Some of the libraries and technologies were acquired through a management buyout of Whitby Research, the pharmaceuticals division of the Ethyl Corporation. The company's novel D2 dopamine agonist for the treatment of Parkinson's disease and now Restless Legs Syndrome is the first such treatment in a patch formulation, and is in advanced clinical trials. Two of the company's adenosine selective compounds are in late-stage clinical trials for the diagnosis and treatment of cardiovascular diseases.
	ADVANCED CARDIOVASCULAR SYSTEMS (Acquired by GUIDANT CORPORATION) 938 Kiely Boulevard #G Mountain View, CA 95051 Phone: (408) 235-3000 Fax: (408) 235-3311 Guidant Web Site Advanced Cardiovascular Systems manufactures and sells percutaneous angioplastic "balloon" catheters. The company was founded in 1981 and was aquired by Eli Lilly in 1984 for stock on an earn-out basis. The Company became a leader in its field, commercializing catheters for angioplasty. It was spun off as part of Guidant in 1994.
	ALTEER 4 Venture, Suite 100 Irvine, CA 92618 Phone: (949) 790-0549 Fax: (949) 789-0509 Alteer Web Site Alteer has built the first integrated software platform that completely eliminates paper and automates the entire workflow in a physician's practice - from scheduling, to charting, billing and patient messaging. Its flagship product, Alteer Office, represents the first practical solution to replace the paper medical record for medical practices of any size, and has been adopted by hundreds of physicians since the product was launched nationally in mid-2001. Designed to accommodate changes in regulatory compliance, Alteer reengineers workflow, patient flow, and information and document management resulting in increased operational efficiency, better managed financial performance and enhanced quality of patient care. The Company is headquartered in Irvine, CA, and markets its products through a direct sales force, as well as distribution partners in several regions across the U.S.
	ATHEROGENICS, INC. 3065 Northwoods Circle Suite 1140, East Tower Norcross, Georgia 30071 Phone: (770) 447-1866 Fax: (770) 447-0481 www.atherogenics.com Atherogenics, Inc. uses a proprietary technology platform for the development of pharmaceutical-based therapies and non-invasive diagnostic tests for the treatment of atherosclerosis. Their goal is to develop products which directly treat atherosclerosis, instead of treating symptoms as do currently available therapies.
	BioSpace, Inc. 245 11th Street San Francisco, California 94103 Phone: (415) 355-6500 Fax: (415) 503-1070  www.biospace.com BioSpace, Inc. is a specialized provider of web-based products and information services to the life sciences. Recognizing the tidal wave of information being published in the life sciences, BioSpace has developed products and services that more efficiently access, deliver and share information. Offered both on the Internet, or an enterprise Intranet, BioSpace's suite of Enterprise Portal Solutions includes an information management tool called BioSpace LinKSTM Solution, and CCIS, a Clinical Competitive Intelligence System. Additionally, the company's premier Website, www.biospace.com is the Internet's most comprehensive life sciences-related information and service resource.
	CardioNet, Inc. 510 Market Street San Diego, CA 92101 Phone: (619) 243-7500 Fax: (619) 243-7700  www.cardionet.com CardioNet, Inc. is the first provider of outpatient cardiac telemetry-monitoring the patient's ECG, heartbeat by heartbeat, at home, at work, or traveling. The technology integrates cardiac monitoring, wireless communications, GPS and proprietary information management systems. Headquartered in San Diego, CardioNet received FDA approval for its core technology in February 2002, began monitoring patients in August through its 24/7/365 monitoring center in Philadelphia. Focused on helping physicians more effectively diagnose and manage patients with cardiac arrhythmias, CardioNet has experienced rapid physician and payor acceptance, achieved profitability at the branch level and is in the process of expanding its service to sites and across the United States.
	Chimerix, Inc. 4401 Eastgate Mall San Diego, CA 92121 Phone: (858) 550-6090 Fax: (858) 550-63900  www.chimerix-inc.com Chimerix, Inc. uses proprietary chemistry to create orally available medicines from bioactive molecules. Application of Chimerix chemistry enhances oral availability, stabilizes drug in plasma, and facilitates absorption of drug by cells in target tissues. Known drugs can be modified to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse reactions. Chimerix technology also enables discovery of new drugs from molecules with chemical properties that would otherwise be unsuitable for pharmaceutical development. Chimerix is applying its technology towards discovery and development of oral drugs for the treatment of smallpox, cytomegalovirus infection, drug-resistant HIV infection, viral hepatitis, and macular degeneration.
	CYTERNEX   11045 Roselle Street, Suite C San Diego, California, 92121 Phone: (858) 866-1605 Fax: (858) 866-1609 www.cyternex.com Cyternex is developing small molecule drug candidates capable of regulating gene expression. In particular, Cyternex is investigating the role of quadruplexes - dynamic, three-dimensional DNA structures - in the regulation of cancer genes and other aspects of tumor biology. The company is based upon technology that originated at the University of Texas and is being developed in collaboration with researchers at the Arizona Cancer Center.
	CYTHERA, INC. 3550 General Atomics Court Bldg.2 Room 503 San Diego, CA 92121 Phone: (858) 455-3708 Fax: (858) 455-3962 www.cytheraco.com CyThera Inc. is a biotechnology company focused on developing cell replacement therapies for the treatment of human degenerative disease. The company's technology enables the expansion and proliferation of functional human stem cells in vitro that can be used to restore specialized tissue function, thereby overcoming the problem of obtaining donor organs. The Company's initial focus is pancreatic islet cell transplantation for the treatment of diabetes. CyThera's first product will be allogenic (donor) cell replacement therapy : a cell transplant product from embryonic stem cells to treat severe diabetics and immune suppressed diabetics patients
	DENDREON, INC. 3005 First Avenue Seattle, WA 98121 Phone: (206) 256-4545 www.dendreon.com Dendreon was founded by Stanford Medical School researchers in order to develop cell activation therapy for the treatment of prostate and other types of cancers. The company has developed a powerful cell-separation technology based on its patented buoyant density solutions, and has harnessed this technology to isolate cells which have been shown to generate powerful, well-tolerated, immune responses specifically targeted against cancer cells.
	DIGIRAD, INC. 9350 Trade Place San Diego, CA 92126-6334 Phone: (800) 947-6134 Fax: (858) 549-7714 www.digirad.com Digirad is the leading designer, developer and manufacturer of solid-state gamma cameras as well as the largest provider of per-day in-office cardiology imaging programs to physician offices through its Digirad Imaging Solutions Division. Digirad has developed and made commercially available in March 2000 the world's first solid-state gamma camera for the nuclear imaging market using a patented, solid-state radiation detection technology. Digirad is a disruptive technology which is allowing many nuclear medicine procedures to move out of the hospital and into the doctor's office. Recent design modifications should also permit Digirad to manufacture cameras for hospital settings.
	DYNATHERM MEDICAL,INC. 819 Mitten Road, Suite 42 Burlingame, CA 94010 Phone: (650) 777-4361 Fax: (650) 777-4370 www.dynathermmedical.com DynaTherm Medical develops and commercializes products for temperature management in surgical, emergency, field and industrial settings. The company's patent protected technology uses non-invasive negative pressure to access the body's natural thermoregulatory system, the AVA's (arteriovenous anastomoses). Using AVA's, which are located on the hands and feet, heat or cold is transmitted directly to the body's core six times more rapidly than with other non-invasive methods in use today. The products have the additional benefit that they do not interfere with common procedures because they are applied at the body's extremities.
	DYNAVAX TECHNOLOGIES CORP. Mailing address:     717 Potter Street, Suite 100     Berkeley, CA 94710 Delivery Address:    1285 66th Street, 1st floor     Emeryville, CA 94608-1116 Phone: (510) 848-5100 Fax: (510) 450-7740 www.dynavax.com Dynavax Technologies is a biopharmaceutical company developing innovative products to treat allergy, asthma and inflammation-mediated diseases, infectious diseases, and cancer. The company's lead products are based on ImmunoStimulatory Sequences (ISS), short DNA sequences that enhance the immune system's ability to fight disease and prevent inflammation. Dynavax has four programs in human clinical trials, including next-generation vaccines for the prevention of hepatitis B, and for the treatment of ragweed allergy that have completed pivotal Phase II clinical trials, as well as early stage programs for asthma and Non-Hodgkins Lymphoma (NHL). Dynavax also has an oral TNF-alpha synthesis inhibitor in preclinical development for rheumatoid arthritis.
	ENDOCYTE 1205 Kent Ave. West Lafayette, IN 47906 Phone: (765) 463-7175 Fax: (765) 463-9271 www.endocyte.com Endocyte is developing imaging and therapeutic agents for the diagnosis and treatment of cancer and autoimmune diseases. The company's novel technology platform uses vitamins such as folate (a derivative of vitamin B-12) which are over expressed in many types of cancers and autoimmune diseases. As a result, their imaging and therapeutic agents target and kill diseased cells while leaving healthy tissues relatively unaffected. The technology is based upon work performed by Dr. Philip S. Low at Purdue University.
	FAVRILLE, INC. 10421 Pacific Center Court Suite 150 San Diego, CA 92121 Phone: (858) 450-5945 Fax: (858) 597-7040 www.favrille.com Favrille, Inc. has developed a proprietary technology platform that utilizes the unique characteristics of each patient's disease to generate patient-specific immunotherapeutics for the treatment of cancer and autoimmune disease. The initial focus is the treatment of cancers of B-cell or T-cell origin. Favrille is currently testing its first therapeutic agent, FavId™ , in Phase II clinical trials.
	GEMIN X P.O. Box 477, Place du Parc Montréal, Québec Canada H2W 4A5 Phone: (514) 281-8989 Fax: (514) 281-1065 www.geminx.com Gemin X Biotechnologies Inc. seeks to discover and develop advanced oncology therapeutics based on the modulation of apoptosis. Gemin X's research focus on the Bcl-2 and p53 pathways has led to the discovery of novel small molecules that selectively restore the cell death program in cancer cells. After advancing these candidates internally through preclinical and early stage clinical development, Gemin X intends to seek co-development alliances to continue later-stage development and commercialization. Gemin X is based in Montréal, Canada, and was founded on technology developed at McGill University in the laboratories of Professors Gordon Shore and Philip Branton.
	GENTERIC, INC. 1650 Harbor Bay Parkway Alameda, CA 94502 Phone: (510) 749-6060 Fax: (510) 749-6062 www.genteric.com Genteric, Inc. is a seed-stage venture that develops gene-based systems to improve and expand the use of protein drugs in vivo. Diseases such as diabetes, hemophilia, anemia, and cancer can be treated or ameliorated by administration of protein drugs, and for a number of diseases proteins are the only effective treatment. Genteric's scientists have invented a novel means of delivering sustained levels of systemic protein drugs which uses the patient's endocrine system to produce and secrete therapeutic proteins into the bloodstream. In compelling proof-of-principle studies, the Company's scientists have demonstrated the ability to treat diabetes and growth deficiency in pre-clinical animal models.
	Harkness Pharmaceuticals c/o Sanderling Ventures 4401 Eastgate Mall San Diego, CA 92121 Phone: (858) 550-6061 Fax: (858) 677-0800 Harkness Pharmacueticals is focused on developing anti-obesity therapeutics. Currently more than 20% of the U.S. population are considered clinically obese yet there remain few therapeutic option available. Harkness is currently exploring the utility of an endogenous peptide in controlling appetite and performing exploratory human clinical trials in collaboration with the Pennington Institute in Louisiana. Harkness is being developed in collaboration with Dr. Byron Rubin and Professor Ed Dennis at UCSD.
	INTERMUNE PHARMACEUTICALS, INC. NASDAQ: ITMN 1710 Gilbreth Road, Suite 301 Burlingame, CA 94010-1317 Phone: (650) 409-2020 Fax: (650) 259-0774 www.intermune.com InterMune Pharmaceuticals is a spin-off from Genentech, Inc. (DNA), with resources and management from Connetics Corp. (CNCT). InterMune is developing products for the treatment of life-threatening conditions such as tuberculosis, fungal disease and severe bacterial infections. The Company has rights to Actimmune®, an FDA-approved product for the prevention and treatment of infections in patients with chronic granulomatous disease. Actimmune® has been used successfully by clinicians to treat a broad array of infections. InterMune has also licensed additional technology from the University of California at San Francisco and the Medical College of Wisconsin for the prevention and treatment of Pseudomonas infections.
	ISTA PHARMACEUTICALS 15279 Alton Parkway, Suite 100 Irvine, CA 92618 Phone: (949) 788-6000 Fax: (949) 788-6010 www.istavision.com ISTA Pharmaceuticals (formerly Advanced Corneal Systems) aims to become a leader in eye care, and is currently pursuing two lead products: a treatment for vitreous hemorrhage and a non-surgical system for vision correction.
	NEOMEND 675 Palomar Avenue Sunnyvale, CA 94085 Phone: (408) 733-0100 Fax: (408) 733-0190 NeoMend, Inc. was formed to design, develop, manufacture and market an array of new products in the area of wound and soft tissue repair. The Company's proprietary technologies include both resorbable biomaterials and minimally invasive medical devices. NeoMend uses these technologies to develop a platform of medical products that utilize a combination of medical device and biomaterial technologies in a single therapy. This type of combination therapy represents the next paradigm in less invasive medicine. Neomend, Inc. is positioned to be the leader in this new field, which has a market size in excess of $1.5 billion per year worldwide considering only the current products under development.
	REGEN BIOLOGICS, INC. 509 Commerce Street East Wing Franklin Lakes, NJ 07417 Phone: (201) 651-5140 Fax: (201) 651-5141 www.regenbio.com ReGen Biologics, Inc. is a biological remodeling company that develops and manufactures implants and medical devices for the regeneration and repair of tissue. Regen Biologics, founded with Sanderling in January 1993, has a technology that is appropriate for a broad range of tissue regeneration applications. ReGen has developed a proprietary type I collagen material as well as several tissue engineering processes that are protected by 22 U.S., 29 international and 12 pending patents. ReGen's flagship product is the Collagen Meniscus Implant* (CMI) which is a type I collagen implant designed for patients with an irreparable meniscus tear or loss of meniscus tissue, typically through an arthroscopic partial meniscectomy procedure. The purpose of the CMI is to assist patients to regain mobility and return to a more vigorous lifestyle, while forestalling or minimizing degenerative joint disease. * The CMI is not available for sale in the United States and it is currently the subject of a U.S. Multicenter Clinical Trial to establish its safety and effectiveness.
	REGENERON PHARMACEUTICALS, INC. NASDAQ: REGN 777 Old Saw Mill Road, Suite 10 Tarrytown, New York 10591 Phone: (914) 347-7000 Fax: (914) 347-2113 www.regeneron.com Regeneron was founded by a clinical neurobiologist and three Nobel Prize winners to develop neurotrophic factors for nerve repair and regeneration. The company has entered into major multi-year R&D programs with Amgen for the development of BDNF and NT3 as human therapeutics, with Glaxo for the screening of small molecule ligands, and with Proctor & Gamble for the development of therapeutic products in other areas.
	SKYEPHARMA, INC.  NASDAQ: SKYE 10450 Science Center Drive San Diego, CA 92121 Phone: (619) 625-2424 Fax: (619) 625-2439 www.skyepharma.com In 1999, SkyePharma, Inc. acquired DepoTech Corporation, a company founded by Sanderling in conjunction with scientists from UC San Diego. Skyepharma has developed DepoFoamSM for injectable, controlled-release drug delivery. The lipid foam encapsulates a drug which, when injected, releases that drug over a predetermined period up to several months. The system is uniquely suitable for delivery of rapidly metabolized or highly toxic compounds, such as those used in chemotherapy and recombinant DNA proteins for the treatment of a variety of disorders. The company currently markets its FDA-approved oncology drug DepoCyte® for treatment of tumors within cerebrospinal fluid.
	STENTOR, INC. 5000 Marina Boulevard Suite 100 Brisbane, CA 94105 Phone: (650) 228-5555 Fax: (650) 228-5566 www.stentor.com Stentor provides enterprise-wide imaging and information solutions to the healthcare industry. Its patent pending iSyntax™ technology (formerly known as Dynamic Transfer Syntax) is the first viable option for the dynamic real time transfer of high quality images across the healthcare enterprise using existing networks and standard PC's. This results in an order of magnitude improvement in image distribution performance, while significantly lowering the cost of distribution. Isyntax™ was invented at the University of Pittsburgh.
	STEREOTAXIS, INC. 4041 Forest Park Ave. St. Louis, MO 63108 Phone: (314) 615-6940 Fax: (314) 615-6948 www.stereotaxis.com/ The continuation of the trend to less invasive surgical or interventional procedures is largely dependent on improved access to the deepest interstices of organ and vascular systems. The longer and more flexible the instrument or the more unstable the target (e.g., the left atrium of a beating heart), the greater the clinical advantage will be if programmable control can be exerted at the working tip of catheters and guidewires. Stereotaxis is developing a solution to the navigation and control of such devices by designing practitioner friendly, digital, distal end control. The Company's core technology is a proprietary interventional workstation and toolkit of disposables uniquely capable of remotely directing and digitally controlling catheter-based therapeutic devices along complex trajectories within the body, making possible important solutions to major interventional challenges.
	TENEX GREENHOUSE VENTURES 839 Mitten Road, Suite 200 Burlingame, CA 94010 Phone: (650) 697-7120 Fax: (650) 697-7119 www.10xgreenhouse.com Tenex Greenhouse Ventures is a Center for Life Science Innovation, which is a joint venture between the Tenex Angel Investment Group and Sanderling Ventures. The Center consists of a headquarters of approximately 2,500 sq. ft. with adjacent lab and office space totaling approximately 9,000 sq.ft. that is available for rent by the portfolio companies with wet lab and machine shop facilities. The Center will draw on the 160 member Tenex organization for deal flow and management for much of the companies formed in the Center. Sanderling will direct the selection of corporate creation with the right to lead follow-on investments in companies formed in the Center. The Greenhouse investor membership consists of ~70 Tenex members who have invested a total of ~$7 million, and Sanderling's investment of four million dollars. This investment pool will be used to invest in approximately 8 early stage investments over the next one to two years.
	TORAX MEDICAL, INC. 6901 East Fish Lake Road, Suite 166 Maple Grove, MN 55369 Phone: (763) 463-4828 Fax: (763) 463-4829 Torax Medical, Inc. is a medical device company located in Minneapolis, MN. Torax is focused on developing technology for minimally invasive treatment of digestive disorders.
	TRIPATH, INC.  NASDAQ: TPTH 8271 154th Ave. N.E., Suite B-101 Redmond, WA 98052 Phone: (425) 869-7284 Fax: (425) 869-5325 www.tripath.com Tripath (formerly NeoPath) was founded in 1989 by a technical team from the University of Washington's Center for Imaging Systems Optimization and the Boeing High Technology Center in Seattle. The company is developing a combination of proprietary software and hardware technologies to provide solutions to complex imaging problems. Their first product, AutoPap® 300, is an automated system for screening pap smears on microscope plates.
	TRINITY BIOSYSTEMS, INC.  2631 Hanover Street, Suite 100B Palo Alto, CA 94304 Phone: (650) 855-9622 Fax: (650) 855-9641 www.trinitybiosystems.com Trinity Biosystems Trinity Biosystems, Inc., is developing a unique platform technology to produce a new class of vaccines and enable the oral delivery of proteins and other peptides. In each of these applications - vaccines and protein delivery - the technology overcomes key technological hurdles that have plagued previous approaches. Trinity's delivery technology has been developed over the past ten years at the National Institutes of Health / National Cancer Institute.
	ULTRABRIDGE, INC. 10706 Beaver Dam Road Suite 201 Hunt Valley, MD 21030 Phone: (410) 527-4900 Fax: (410) 527-4937 www.ultrabridge.com UltraBridge is a technology solution provider to the long term care industry. Built upon a deep knowledge and understanding of the industry operations, UltraBridge provides its clients with a comprehensive management solution to their data and business reporting needs using outsourcing. Their services include: hosting and integrating the industries leading software for clinical, financial, marketing and HR applications across multiple departments, facilities and geographic locations. Furthermore, UltraBridge provides a wide array of custom real-time management reporting tools.
	VENTRITEX (Acquired by ST. JUDE MEDICAL) 701 E. Evelyn Avenue Sunnyvale, CA 94086-6527 Phone: (408) 738-4883 Fax: (408) 738-4953 www.sjm.com/ Ventritex is a leader in the field of implantable defibrillators. The device is designed to monitor the heart, determine if the heart is undergoing fibrillation, defibrillate the heart, record an EKG and report data on demand to the physician. The market for the device is in patients who are candidates for acute myocardial infarction due to degenerative disease or patients who have previously suffered heart attacks.
	VICAL, INC. NASDAQ: VICL 4510 Executive Drive, Suite 215 San Diego, CA 92121 Phone: (619) 453-9900 Fax: (619) 453-5885 www.vical.com Vical's gene therapy business is based on the use of "naked DNA" technology involving injection of DNA directly into human cells. This genetic material is then able to express proteins with therapeutic activity for use in vaccines and the treatment of several types of cancers.
	XOMA  NASDAQ: XOMA 2910 Seventh Street Berkeley, CA 94710 Phone: (415) 644-1170 Fax: (415) 644-0539 www.xoma.com Xoma was founded to synthesize and manufacture immunotoxins and other monoclonal antibodies to be used in the treatment of a variety of human diseases. Three areas of interest include cancer, septic shock and graft-versus-host disease (GvHD), a fatal illness in bone marrow transplants.

---